Saturday 17 October 2026
Export CRIS’s income statement to Excel — free account
Curis, Inc.
CRIS Healthcare Biotechnology
Curis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.4 million, down 13.4% from fiscal 2024. In the quarter to June 2026, revenue fell 66.0%, EPS grew 70.4% and free cash flow fell 20.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.41
0.10
−19.61%
Follow CRIS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
2.23 | 1.38 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(4.67) | (2.05) | — | — | |
P/B ratio |
0.00 | 2.39 | — | — | |
Price to Tangible BV |
0.00 | 0.00 | — | — | |
EV/Sales |
1.56 | 0.97 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(0.60) | (0.34) | — | — | |
EV/FCF |
(0.60) | (0.33) | — | — | |
Quick Ratio |
0.62 | 0.36 | 1.00 | 0.41 | |
Current Ratio |
0.70 | 0.49 | 1.11 | 0.49 | |
Net Debt/EBITDA |
1.31 | (0.26) | 1.30 | 0.57 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.33 | 0.31 | 0.00 | 0.00 | |
Operating CF/Net income |
0.72 | (0.33) | 0.37 | 1.12 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(7.82) | 22.65 | — | — | |
Research and Development Expense of Revenue |
202.52% | 511.86% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
115.02% | 253.34% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.33 | 0.45 | 0.30 | 0.47 | |
Share Based Compensation of Revenue |
29.09% | 69.86% | 0.00% | 0.00% | |
Graham Net Nets |
(1.09) | (0.58) | — | — | |
Graham Number |
175.92 | 0.00 | — | — | |
Earnings Yield |
(221.08%) | (120.20%) | — | — | |
Free Cash Flow Yield |
(117.20%) | (211.91%) | — | — | |
Revenue per Share |
4.05 | 1.73 | 0.00 | 0.00 | |
Operating CF per Share |
(7.10) | (9.68) | (9.30) | (4.52) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(7.10) | (9.68) | (9.30) | (4.52) | |
Cash per Share |
11.54 | 7.69 | 15.49 | 2.63 | |
Shareholders Equity per Share |
(18.74) | 8.30 | 13.12 | 2.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(18.74) | 8.30 | 13.12 | 2.20 | |
Free Cash Flow |
(5.57) | (6.37) | (9.00) | (9.65) | |
Working Capital |
(6.00) | (7.16) | 1.64 | (6.95) | |
Net Current Asset Value |
(28.42) | (7.59) | (0.37) | (7.55) | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
3.11 | — | — | — | |
Average Payables |
4.13 | 4.32 | 5.92 | 4.74 | |
Average Assets |
35.06 | 30.62 | 34.51 | 24.10 | |
Average Common Equity |
(11.71) | (0.27) | 3.05 | (4.65) |
Columns are period end dates